Welcome to PharmaBlue

Exploitant Partner for Innovative Pharmaceutical Companies

PharmaBlue aims to contribute to a world where patients with unmet medical needs have better access to a variety of safe, effective healthcare products, and innovative treatments.

We are your Medium/Long term partner to get and run your Early Access Program in France.

We provide Exploitant services to our clients for rapidly marketing their approved medicines in France (orphan or unmet medical need).

Talk to an expert

Exploitant for Innovative Pharma Companies

Why Partnering with PharmaBlue?

You are looking to find a partner for Early Access Programs in France

When a pharmaceutical company is primarily focusing on development but would like to outsource Early Access Programs in France and Exploitant responsibilities in the field of rare or serious disease & unmet medical need, why is Pharma Blue a good choice?

From its creation, PharmaBlue has been involved in the efficient management of EAPs (Early Access Programs, known as Expanded Access Program in the US) and early phase of post marketing authorization activities in France.
Developing strong expertise in supporting Pharma companies to obtain early access authorization and manage them, we have gained a good reputation in the field of rare or serious disease & unmet medical need.

PharmaBlue has built a robust quality management system to provide continuous and specific support to foreign companies willing to introduce new products to the French market.

PharmaBlue offers the possibility to hold the Exploitant status and overlook pharmaceutical operations on the French Market.

PharmaBlue has an experienced team in quality management and pharmacovigilance that is used to cooperate with firms in Europe and in the US.

You are a pharmaceutical company considering to establish an affiliate in France

You are planning to create an affiliate in France, how PharmaBlue can support you with this project?

PharmaBlue can provide support to your plan of creation of a licensed pharmaceutical affiliate in France (with an Exploitant status) with a framework of progressive disengagement as your new business gets more resources and staffing

In addition, Cencora PharmaLex experts’ team will be able to support your affiliate obtaining the licensed Exploitant status and extend support and training to newly formed organization to ensure a smooth transfer of competency.

Lean more about PharmaBlue

We are supporting many biotechs innovators with French Early Access Programs set-up. We will become your Medium/Long Term Partner providing Early Access and Exploitant services for rapidly market your approved medicines in France.

*This video containes marketing statements related to PharmaBlue SAS, a subsidiary of PharmaLex France SAS. PharmaBlue and PharmaLex are each subsidiaries of Cencora, Inc. PharmaLex and Cencora strongly encourage viewers to review all available information and to rely on their own experience and expertise in making commercialization decisions in the French market. The contents of this video are owned by PharmaBlue and reproduction of this video is not permitted without the consent of PharmaBlue.

Strategic services

Early Access Programs

Early & Expanded Access Programs in France

Exploitant Operations for Commercialised Products

Our Exploitant Services

Pharmaceutical operations in France

Compliance

Promotional & Non Promotional Material Review

Market Access

EAP Worldwide

Distribution and Logistic

+10.000

Patients

We have been managing more than 10,000 patients to date

+58

Projects

Developed by our teams of experts to support companies launch their innovative asset in France

+15

EAPs

More than fifteen percents of the total numbers of EAP Dossiers approved by the Authorities in France in 1 year were submitted by PharmaBlue

The four Pillars of PharmaBlue

PharmaBlue operates since more than 10 years in the pharmaceutical industry partnering with life sciences companies in their ability to develop innovative drug products in compliance with regulations.
Our collaborative approach is built on our intrinsic understanding of the needs of pharmaceutical companies in the life sciences industry.
We are committed to ensure that each client benefit our expertise and support in its early access and Exploitant strategy decision-making processes.
We support pharmaceutical companies in their corporate strategy providing consulting services to overcome real and perceived challenges of the regulatory environment, in order to launch their innovative treatment solutions that will improve patients’ quality of life.

PharmaBlue has extensive experience partnering with biotech and multinational pharmaceutical companies developing drugs for serious unmet medical needs such as Orphan Drugs in the field of rare or serious disease.
We also partner with pharmaceutical companies looking to optimize time to market and provide access to our extensive experience in registration strategies.
As a pharma consultancy, we provide our clients with highly qualified consultants able to plug to their organization in a specific regulatory areas or target market.

We support pharmaceutical companies with strategic consulting through all stages of product development, from clinical research, registration to the launch of innovative products on the market.
With our collaborative approach we aim to ensure efficient and effective interactions with health authorities protecting your projects and reputation.

We, as partner for innovative pharmaceutical companies, offer access to cross functional teams and tailored solution to help life sciences organizations to reach their businesses objectives achieving optimum support for early access programs.
Our services will give you an additional value as we can partner with your existing regulatory affairs team, providing advice and access to our expertise and experts personal experience in healthcare industries.